{"organizations": [], "uuid": "722788089cbe5ddd86dd53048e9c60d10f971701", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-myriad-genetics-to-present-at-two-upcoming-healthcare-conferences.html", "country": "US", "domain_rank": 767, "title": "Myriad Genetics to Present at Two Upcoming Healthcare Conferences", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-27T15:05:00.000+02:00", "replies_count": 0, "uuid": "722788089cbe5ddd86dd53048e9c60d10f971701"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-myriad-genetics-to-present-at-two-upcoming-healthcare-conferences.html", "ord_in_thread": 0, "title": "Myriad Genetics to Present at Two Upcoming Healthcare Conferences", "locations": [], "entities": {"persons": [{"name": "mark c. capone", "sentiment": "none"}, {"name": "capone", "sentiment": "none"}], "locations": [{"name": "lake city", "sentiment": "none"}, {"name": "massachusetts", "sentiment": "none"}, {"name": "florida", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}, {"name": "miami", "sentiment": "none"}], "organizations": [{"name": "myriad genetics", "sentiment": "negative"}, {"name": "myriad genetics, inc.", "sentiment": "neutral"}, {"name": "barclays global healthcare conference", "sentiment": "none"}, {"name": "cowen healthcare conference", "sentiment": "none"}, {"name": "about myriad genetics myriad genetics inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SALT LAKE CITY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at two upcoming investor conferences. On March 13, 2018, Mr. Capone will present at the 38th annual Cowen Healthcare Conference in Boston, Massachusetts at 8:40 a.m. ET. On March 14, 2018, Mr. Capone will present at the Barclays Global Healthcare Conference in Miami, Florida at 2:35 p.m. ET.\nThe presentations will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriadâ€™s website at www.myriad.com .\nAbout Myriad Genetics\nMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .\nMyriad, the Myriad logo, BART, BRAC Analysis , Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.\nMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com\nSource:Myriad Genetics, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/2d4060a7-2af2-4830-ad77-4831d2c21b49", "https://www.globenewswire.com/Tracker?data=-pcdrTYXZn-lxCFB5myg-J1Sx-7erQY3Vpph-O8ZniAJVCplKYF6w0OL_mowaQ86GxYRUNFliLjsSnNrn2rakg==", "https://www.globenewswire.com/Tracker?data=-pcdrTYXZn-lxCFB5myg-HRalSFmmOvmdTSddaZZqL7EleAhZn0Pjjsc7V6zdTOX1HJCyi2dDbRu7Y-7oovFew=="], "published": "2018-02-27T15:05:00.000+02:00", "crawled": "2018-02-27T17:28:53.009+02:00", "highlightTitle": ""}